Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Effect of β-1,3-1,6-D-glukan (polysaccharide peptide) from miselia ganoderma lucidum extract as antioxidant and antiinflammation towards left ventricular systolic function in cardiometabolic patients

Heart Science Journal · Vol. 5 No. 4 (2024) · hlm. 55–59

DOI
10.21776/ub.hsj.2024.005.04.9
ISSN
2721-9984, 2721-9976
Terbit
2024-10-28
Penerbit
Universitas Brawijaya
Bahasa
en

Abstrak

Background: Cardiometabolic disease (CMD) describes a metabolic condition often associated with cardiovascular disease. It has been revealed that the Ganoderma lucidum polysaccharide peptide (GLPP) possesses anti-inflammatory and antioxidant qualities. Objective: This study aimed to find out how GLPP affected oxidative stress, inflammation, and left ventricular function in individuals with cardiometabolic syndrome.Methods: A multicenter double-blinded randomized controlled trial was carried out. Subjects with cardiometabolic syndrome received either GLPP or a placebo for ninety days. Before taking the initial treatment and one day following the last treatment intake, blood samples were taken from every participant. The enzyme-linked immunosorbent assay was used to evaluate the levels of serum tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), malondialdehyde (MDA), and high-sensitivity-C-Reactive Protein (hs-CRP) while the colorimetric test was used to measure the levels of superoxide dismutase (SOD). Global longitudinal strain (GLS) and Left ventricle ejection fraction (LVEF) were measured by single echocardiographer expert validation.Results: The MDA level was decreased in the GLPP treatment group (mean 56.0 ± 71.4 ng/mL to 27.7 ± 12.0 ng/mL, p= 0.023) compared to the control group (mean 39.3 ± 29.2 ng/mL to 38.3 ± 17.7 ng/mL, p= 0.719). However, the SOD level remained constant in the GLPP treatment (mean 122.2 ± 176.1 U/mL to 93.0 ± 40.9 U/mL, p=0.925) instead of significantly declining in the control group (mean 102.0 ± 67.3 U/mL to 64.0 ± 52.0 U/mL, p=0.016). The marker of TNF-α and hsCRP were significantly decreased in all groups (both p 0.05).Conclusion: Patients with cardiometabolic syndrome may benefit from GLPP treatment for 90 days in terms of reduced inflammation, oxidative stress, and improved systolic left ventricular performance.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 296 tautan kepenulisan bersama · 8 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • RSUD Prof. Dr. Saiful Anwar Malang
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Mohammad Saifur RohmanUniversity of Brawijaya28
Cholid Tri TjahjonoUniversity of Brawijaya20
Novi KurnianingsihUniversity of Brawijaya18
Ardian RizalUniversity of Brawijaya16
Indra PrasetyaUniversity of Brawijaya14
Budi SatrijoUniversity of Brawijaya13
Setyasih AnjarwaniUniversity of Brawijaya13
Heny MartiniUniversity of Brawijaya11
Wella KarolinaUniversity of Brawijaya7
Sasmojo WiditoUniversity of Brawijaya7
Yoga WaranugrahaUniversity of Brawijaya5
Muhammad Rizki FadlanUniversity of Brawijaya5
Nikhen NoverikeUniversity of Brawijaya4
Valerinna YogibuanaAfiliasi tidak diketahui4
Lukitasari Ayu Galuh ArdhiUniversity of Brawijaya4
Putri Annisa KamilaUniversity of Brawijaya4
Ayu Asri Devi AdityawatiUniversity of Brawijaya4
Ratna PancasariUniversity of Brawijaya3
Veny KurniawatiUniversity of Brawijaya2
Dadang HendrawanUniversity of Brawijaya2
Imelda KrisnasariUniversity of Brawijaya2
Tri AstiawatiUniversity of Brawijaya2
Valerinna Yogibuana Swastika PutriUniversity of Brawijaya2
N KaputrinUniversity of Brawijaya2
Olivia HandayaniUniversity of Brawijaya2
Liemena Harold AdrianRSUD Prof. Dr. Saiful Anwar Malang2
Krishna Ari NugrahaUniversity of Brawijaya2
Fandy HazzyUniversity of Brawijaya2
Yudi Putra ApridityaUniversity of Brawijaya2
Imam Mi'raj SuprayogaUniversity of Brawijaya2
Yoseph Budi UtomoUniversity of Brawijaya1
Ryan RamadhanUniversity of Brawijaya1
Ardian RizalUniversity of Brawijaya1
Renny SuwarniatyUniversity of Brawijaya1
Taufieq Ridlo MakhmudUniversity of Brawijaya1
Faris Wahyu NugrohoUniversity of Brawijaya1
Annisa Dallilatul HasanahUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://heartscience.ub.ac.id/index.php/heartscience/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Effect of β-1,3-1,6-D-glukan (polysaccharide peptide) from miselia ganoderma lucidum extract as antioxidant and antiinflammation towards left ventricular systolic function in cardiometabolic patients</dc:title>
	<dc:creator xml:lang="en">Aryanugraha, Teguh</dc:creator>
	<dc:creator xml:lang="en">Sargowo, Djanggan</dc:creator>
	<dc:creator xml:lang="en">Rahimah, Anna Fuji</dc:creator>
	<dc:subject xml:lang="en">oxidative stress</dc:subject>
	<dc:subject xml:lang="en">inflammation</dc:subject>
	<dc:subject xml:lang="en">cardiometabolic syndrome</dc:subject>
	<dc:subject xml:lang="en">echocardiography</dc:subject>
	<dc:subject xml:lang="en">Ganoderma lucidum</dc:subject>
	<dc:description xml:lang="en">Background: Cardiometabolic disease (CMD) describes a metabolic condition often associated with cardiovascular disease. It has been revealed that the Ganoderma lucidum polysaccharide peptide (GLPP) possesses anti-inflammatory and antioxidant qualities. Objective: This study aimed to find out how GLPP affected oxidative stress, inflammation, and left ventricular function in individuals with cardiometabolic syndrome.Methods: A multicenter double-blinded randomized controlled trial was carried out. Subjects with cardiometabolic syndrome received either GLPP or a placebo for ninety days. Before taking the initial treatment and one day following the last treatment intake, blood samples were taken from every participant. The enzyme-linked immunosorbent assay was used to evaluate the levels of serum tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), malondialdehyde (MDA), and high-sensitivity-C-Reactive Protein (hs-CRP) while the colorimetric test was used to measure the levels of superoxide dismutase (SOD). Global longitudinal strain (GLS)  and Left ventricle ejection fraction (LVEF) were measured by single echocardiographer expert validation.Results: The MDA level was decreased in the GLPP treatment group (mean 56.0 ± 71.4 ng/mL to 27.7 ± 12.0 ng/mL, p= 0.023) compared to the control group (mean 39.3 ± 29.2 ng/mL to 38.3 ± 17.7 ng/mL, p= 0.719). However, the SOD level remained constant in the GLPP treatment (mean 122.2 ± 176.1 U/mL to 93.0 ± 40.9 U/mL, p=0.925) instead of significantly declining in the control group (mean 102.0 ± 67.3 U/mL to 64.0 ± 52.0 U/mL, p=0.016). The marker of TNF-α and hsCRP were significantly decreased in all groups (both p&amp;lt;0.05), but IL-6 was only significantly decreased in the control group (mean 1149.3 ± 581.7 pg/mL to 744.8 ± 336.5 pg/mL, p=0.010). The GLS was significantly decreased in the GLPP treatment group (-16.1 ± 4.1 to -17.5 ± 4.8, p=0.048) but there was no difference in LVEF in both groups (p&amp;gt;0.05).Conclusion: Patients with cardiometabolic syndrome may benefit from GLPP treatment for 90 days in terms of reduced inflammation, oxidative stress, and improved systolic left ventricular performance.</dc:description>
	<dc:publisher xml:lang="en">Universitas Brawijaya</dc:publisher>
	<dc:date>2024-10-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://heartscience.ub.ac.id/index.php/heartscience/article/view/15768</dc:identifier>
	<dc:identifier>10.21776/ub.hsj.2024.005.04.9</dc:identifier>
	<dc:source xml:lang="en">Heart Science Journal; Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease; 55-59</dc:source>
	<dc:source>2721-9984</dc:source>
	<dc:source>2721-9976</dc:source>
	<dc:source>10.21776/ub.hsj.2024.005.04</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://heartscience.ub.ac.id/index.php/heartscience/article/view/15768/457</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Teguh Aryanugraha</dc:rights>
</oai_dc:dc>